Poorer Survival of Male Breast Cancer Compared with Female Breast Cancer Patients May Be Due to Biological Differences

ArticleinJapanese Journal of Clinical Oncology 43(10) · August 2013with20 Reads
DOI: 10.1093/jjco/hyt116 · Source: PubMed
The objective of the study was to compare disease-free survival and overall survival in a group of matched males and females with breast cancer, and to analyze possible treatment- and gender-related differences. We retrospectively analyzed the data of 150 operable male breast cancer patients treated in our hospital from December 1980 to June 2012. Each male breast cancer patient recorded in the database was matched with two female breast cancer patients of equal stage. Prognosis in terms of disease-free survival and overall survival was evaluated. The mean age at diagnosis was 58.6 ± 9.7 years for males and 57.2 ± 10.3 years for females. The median follow-up was 69 months for males and 81 months for females. Significant differences were identified for tumor location, hormone receptor status, molecular subtypes and hormone therapy between the two groups. Monofactorial analysis demonstrated that tumor size, lymph node state, American Joint Committee on Cancer stage, molecular subtypes and adjuvant chemotherapy treatment were prognostic factors in male breast cancer patients. The 5- and 10-year disease-free survival rates were 65.6 and 40.1% for males, and 74.9 and 51.5% for females, respectively. The 5- and 10-year overall survival rates were 72.9 and 53.9% for males, and 83.2 and 68.5% for females, respectively. There was significantly difference in disease-free survival and overall survival between the two matched groups (P = 0.002). Male breast cancer patients had inferior outcome despite of equal stage in comparison with matched female breast cancer patients, which demonstrates that biological differences may contribute to the worse prognosis.
October 2012 · Oncology letters · Impact Factor: 1.55
    Male breast cancer is a rare disease. The aim of this study was to compare overall survival (OS) and disease-free survival (DFS) in a group of matched males and females with breast cancer. The clinical data and survival status of 42 operable male breast cancer (MBC) cases treated at the Central Hospital of Tai'an from 1982 to 2006 were collected. Each MBC patient recorded in the database was... [Show full abstract]
    February 2009 · Cancer Science · Impact Factor: 3.52
      Little information is available on the survival of male breast cancer patients because the disease is extremely rare in men. Moreover, previous reports on the prognosis of male breast cancer have been conflicting. We took advantage of a number of large, nationwide registries in Sweden to evaluate the prognostic value of sex in breast cancer patients. A population-based cohort of 269 male and... [Show full abstract]
      August 2015 · PLoS ONE · Impact Factor: 3.23
        Male breast cancer (MBC) is known to be rare compared with female breast cancer (FBC) and to account for only 1% of all breast cancers. To date, male patients diagnosed with breast cancer are normally treated based on the guidelines for FBC. Specifically, studies have found that diagnosing and treating MBC patients under the guidelines for the treatment of post-menopausal FBC are more... [Show full abstract]
        October 2014 · Clinical Breast Cancer · Impact Factor: 2.11
          Background Breast cancer occurs rarely in males accounting for approximately 1% of all breast carcinomas. Data on prognosis principally derives from retrospective studies and from extrapolation of female breast cancer series. Patients and methods A total of 99 male patients with invasive breast cancer were matched with 198 female breast cancer patients who had surgery at the same institution... [Show full abstract]
          Discover more